Cases & Deals

  • Home
  • Practices
  • Nuvalent establishes global patent portfolios for small molecule ROS1-selective inhibitors, ALK-selective inhibitors, and HER2-selective tyrosine kinase inhibitors

Share

Nuvalent establishes global patent portfolios for small molecule ROS1-selective inhibitors, ALK-selective inhibitors, and HER2-selective tyrosine kinase inhibitors

November 2022

Client(s) Nuvalent, Inc.

Jones Day represents Nuvalent, Inc. in the establishment and prosecution of global patent portfolios related to small molecule ROS1-selective inhibitors, ALK-selective inhibitors, and HER2-selective tyrosine kinase inhibitors for the treatment of cancer.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.